PRETREATMENT ENDORECTAL MAGNETIC RESONANCE IMAGING AND MAGNETIC RESONANCE SPECTROSCOPIC IMAGING FEATURES OF PROSTATE CANCER AS PREDICTORS OF RESPONSE TO EXTERNAL BEAM RADIOTHERAPY

Purpose: To evaluate whether pretreatment combined endorectal magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) findings are predictive of outcome in patients who undergo external beam radiotherapy for prostate cancer. Methods and Materials: We retrospectively identified 67 men with biopsy-proven prostate cancer who underwent combined endorectal MRI and MRSI at our institution between January 1998 and October 2003 before whole-pelvis external beam radiotherapy. A single reader recorded tumor presence, stage, and metabolic abnormality at combined MRI and MRSI. Kaplan-Meier survival and Cox univariate and multivariate analyses explored the relationship between clinical and imaging variables and outcome, using biochemical or metastatic failure as endpoints. Results: After a mean follow-up of 44 months (range, 3-96), 6 patients developed both metastatic and biochemical failure, with an additional 13 patients developing biochemical failure alone. Multivariate Cox analysis demonstrated that the only independent predictor of biochemical failure was the volume of malignant metabolism on MRSI (hazard ratio [HR] 1.63, 95 % confidence interval [CI] 1.29-2.06; p < 0.0001). The two independent predictors of metastatic failure were MRI tumor size (HR 1.349 95 % CI 1.03-1.73; p = 0.028) and the finding of seminal vesicle invasion on MRI (HR 28.059 95% CI 3.96-198.67; p = 0.0008). Conclusions: In multivariate analysis, MRI and MRSI findings before EBRT in patients with prostate cancer are more accurate independent predictors of outcome than clinical variables, and in particular, the findings of seminal vesicle invasion and extensive tumor predict a worse prognosis. (c) 2009 Elsevier Inc.